Article
Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer.
Clinical and molecular hepatology - 1 Apr 2026
Li Shijie, Shan Yukai, Chen Tianen, Topatana Win, Juengpanich Sarun, Lu Ziyi, Sun Yuchao, Xie Tianao, Ruijing Ruijing, Hou Lidan, Chen Jiang, Chen Guojun, Lv Jiemin, Ma Xianjue, Guo Pengjuan, Duda Dan Gabriel, Cai Xiujun, Chen Mingyu
Abstract excerpt
BACKGROUND/AIMS: Biliary tract cancer (BTC) frequently harbors KRAS mutations, which are associated with resistance to traditional treatment and a poor prognosis. Synthetic lethality (SL) strategy may provide other targets of KRAS. Therefore, we aim to identify and validate potential therapeutic targets of KRAS for the treatment of BTC via SL. METHODS: The dependency (DepMap) projects were used to predict the...
Topics
Join the communities discussing this publication.